Key result
The overall prevalence of NAFLD in T2DM patients was 58.67%, and increased Body Mass Index was significantly associated with a higher risk of NAFLD (OR 1.241).
Why the study?
Although NAFLD is strongly associated with T2DM, the diagnosis of NAFLD in patients with T2DM remains a challenge.
Cross-Sectional (n=2,405)
No
Odds Ratio: 1.241 (95% CI 1.118–1.378)
p-value: p=<0.001
In patients with type 2 diabetes, NAFLD is highly prevalent (58.67%), and a combined predictive indicator including BMI, WHR, triglycerides, and ALT can effectively screen for its presence.
Supports NAFLD screening consideration in T2DM; leaves open causal links and prospective validation.
Although non-alcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes mellitus (T2DM), the diagnosis of NAFLD for T2DM patients remains a challenge.This study aimed to investigate the prevalence and risk factors for the NAFLD in T2DM outpatients.This is a retrospective, cross-sectional study that included 2405 T2DM patients treated and admitted for glucose control into the Endocrinology Department of our hospital from April 2017 to March 2019. Using strict exclusion criteria, the target patients were screened and divided into two groups: NAFLD patients (study group) and non-NAFLD patients (control group). Subsequently, 34 factors were compared between the two groups. Furthermore, multivariate analysis of the NAFLD risk factors was performed using logistic regression. Finally, the diagnostic significance of individual biochemical predictors, as well as the combined predictive indicator (CPI), for NAFLD was estimated using receiver operating characteristic (ROC) curve analysis.In this study, the overall prevalence of NAFLD in T2DM patients was 58.67%. Of the target patients, 17 factors were identified by univariate analysis to be associated with NAFLD, and 8 factors were found to be significant predictors for NAFLD using binary logistic regression modeling. Furthermore, the CPI and C-Peptide represent high diagnostic value for NAFLD in T2DM patients.This study provides a more comprehensive risk factor analysis for NAFLD in T2DM patients. These data can be used to provide timely diagnosis and effective management of NAFLD.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2021) conducted a cross-sectional in Type 2 diabetes mellitus and non-alcoholic fatty liver disease (n=2,405). Body Mass Index (BMI) vs. Lower BMI was evaluated on Risk of NAFLD associated with increased Body Mass Index (OR 1.241, 95% CI 1.118-1.378, p=<0.001). The overall prevalence of NAFLD in T2DM patients was 58.67%, and increased Body Mass Index was significantly associated with a higher risk of NAFLD (OR 1.241).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: